Title : Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways.

Pub. Date : 2014 Feb

PMID : 23515587






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 EGCG treatment also counteracted the activity of TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappaB pathways. epigallocatechin gallate forkhead box O1 Rattus norvegicus
2 CONCLUSIONS: Epigallocatechin gallate (EGCG) reduced the severity of liver injury in an experimental model of NAFLD associated with lower concentration of pro-fibrogenic, oxidative stress, and pro-inflammatory mediators partly through modulating the activities of TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappaB pathways. epigallocatechin gallate forkhead box O1 Rattus norvegicus
3 CONCLUSIONS: Epigallocatechin gallate (EGCG) reduced the severity of liver injury in an experimental model of NAFLD associated with lower concentration of pro-fibrogenic, oxidative stress, and pro-inflammatory mediators partly through modulating the activities of TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappaB pathways. epigallocatechin gallate forkhead box O1 Rattus norvegicus